MX2016012932A - Procedimientos novedosos para inducir una respuesta inmune. - Google Patents

Procedimientos novedosos para inducir una respuesta inmune.

Info

Publication number
MX2016012932A
MX2016012932A MX2016012932A MX2016012932A MX2016012932A MX 2016012932 A MX2016012932 A MX 2016012932A MX 2016012932 A MX2016012932 A MX 2016012932A MX 2016012932 A MX2016012932 A MX 2016012932A MX 2016012932 A MX2016012932 A MX 2016012932A
Authority
MX
Mexico
Prior art keywords
inducing
immune response
novel methods
methods
administrations
Prior art date
Application number
MX2016012932A
Other languages
English (en)
Spanish (es)
Inventor
Ripley Ballou William Jr
Ange Demoitie Marie-
Noelle Renelle DONNER Marie-
Ouaked Nadia
Theophile TEMMERMAN Stephane
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2016012932A publication Critical patent/MX2016012932A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2016012932A 2014-04-02 2015-04-02 Procedimientos novedosos para inducir una respuesta inmune. MX2016012932A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1405921.6A GB201405921D0 (en) 2014-04-02 2014-04-02 Novel methods for inducing an immune response
PCT/EP2015/057423 WO2015150567A1 (en) 2014-04-02 2015-04-02 Novel methods for inducing an immune response

Publications (1)

Publication Number Publication Date
MX2016012932A true MX2016012932A (es) 2016-12-07

Family

ID=50737873

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016012932A MX2016012932A (es) 2014-04-02 2015-04-02 Procedimientos novedosos para inducir una respuesta inmune.
MX2016012982A MX2016012982A (es) 2014-04-02 2015-04-02 Procedimientos novedosos para inducir una respuesta inmunitaria.
MX2022013912A MX2022013912A (es) 2014-04-02 2016-09-30 Procedimientos novedosos para inducir una respuesta inmunitaria.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2016012982A MX2016012982A (es) 2014-04-02 2015-04-02 Procedimientos novedosos para inducir una respuesta inmunitaria.
MX2022013912A MX2022013912A (es) 2014-04-02 2016-09-30 Procedimientos novedosos para inducir una respuesta inmunitaria.

Country Status (18)

Country Link
US (3) US10624961B2 (enExample)
EP (2) EP3125930B1 (enExample)
JP (2) JP6655549B2 (enExample)
KR (2) KR20160132115A (enExample)
CN (2) CN106456739A (enExample)
AR (1) AR099960A1 (enExample)
AU (1) AU2015239025B2 (enExample)
BE (1) BE1022355B1 (enExample)
BR (2) BR112016022787A2 (enExample)
CA (2) CA2943711A1 (enExample)
EA (1) EA037405B1 (enExample)
ES (2) ES2961840T3 (enExample)
GB (1) GB201405921D0 (enExample)
IL (1) IL247493B (enExample)
MX (3) MX2016012932A (enExample)
SG (1) SG11201607086QA (enExample)
WO (2) WO2015150568A1 (enExample)
ZA (1) ZA201605955B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
FR3066920A1 (fr) 2017-05-30 2018-12-07 Glaxosmithkline Biologicals S.A. Nouveaux procedes de fabrication d'un adjuvant
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
CN115768892A (zh) 2020-03-09 2023-03-07 戴纳瓦克斯技术公司 包含tlr9激动剂的带状疱疹疫苗
CN113125756B (zh) * 2020-07-15 2022-10-25 南京岚煜生物科技有限公司 抗体标准品赋值和抗原中和当量确定的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US152200A (en) * 1874-06-16 Improvement in garters
US1002607A (en) * 1905-08-28 1911-09-05 John Willard Taylor Paper pulley.
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
PL376792A1 (pl) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
ES2371175T3 (es) 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
KR20130110233A (ko) * 2005-04-29 2013-10-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2087128A4 (en) * 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
HUE031411T2 (en) * 2007-03-02 2017-07-28 Glaxosmithkline Biologicals Sa New Methods and Preparations
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
PT2315834T (pt) * 2008-07-25 2018-08-10 Glaxosmithkline Biologicals Sa A proteína rv2386c de tuberculose, composições e as suas utilizações
LT2315597T (lt) * 2008-07-25 2018-02-12 Glaxosmithkline Biologicals S.A. Naujos kompozicijos ir būdai
SI2315773T1 (sl) * 2008-07-25 2016-12-30 Glaxosmithkline Biologicals S.A. Polipeptidi, polinukleotidi in sestavki za uporabo pri zdravljenju latentne tuberkuloze
HRP20161608T1 (hr) * 2010-01-27 2017-01-13 Glaxosmithkline Biologicals Sa Modificirani tuberkulozni antigeni
CA2819297A1 (en) * 2010-12-14 2012-06-21 Glaxosmithkline Biologicals S.A. Mycobacterium antigenic composition
US20170056345A1 (en) * 2014-02-18 2017-03-02 Stc.Unm Booster drug therapy for mycobacterium infections
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
BR112016023778A2 (pt) * 2014-04-24 2017-10-17 Statens Seruminstitut proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Also Published As

Publication number Publication date
EP3125930B1 (en) 2020-12-02
AU2015239025B2 (en) 2018-01-25
EP3125929A1 (en) 2017-02-08
SG11201607086QA (en) 2016-09-29
JP2017511324A (ja) 2017-04-20
KR20160132115A (ko) 2016-11-16
AR099960A1 (es) 2016-08-31
KR102762440B1 (ko) 2025-02-03
EP3125930A1 (en) 2017-02-08
JP6645982B2 (ja) 2020-02-14
ZA201605955B (en) 2019-04-24
KR20230075525A (ko) 2023-05-31
US10688168B2 (en) 2020-06-23
EP3125929B1 (en) 2023-11-01
US20170136110A1 (en) 2017-05-18
BE1022355B1 (fr) 2016-03-26
CN106456738B (zh) 2021-06-29
JP6655549B2 (ja) 2020-02-26
GB201405921D0 (en) 2014-05-14
IL247493A0 (en) 2016-11-30
MX2016012982A (es) 2016-12-07
CA2943007C (en) 2024-01-09
BR112016022787A2 (pt) 2018-03-27
US20200306353A1 (en) 2020-10-01
ES2961840T3 (es) 2024-03-14
EA037405B1 (ru) 2021-03-25
US20170112914A1 (en) 2017-04-27
MX2022013912A (es) 2022-12-13
BE1022355A1 (fr) 2016-02-16
EP3125929B8 (en) 2023-12-27
WO2015150567A1 (en) 2015-10-08
EP3125929C0 (en) 2023-11-01
JP2017511327A (ja) 2017-04-20
CN106456738A (zh) 2017-02-22
IL247493B (en) 2022-08-01
BR112016022463A2 (pt) 2017-10-10
US11951161B2 (en) 2024-04-09
EA201691638A1 (ru) 2017-04-28
WO2015150568A1 (en) 2015-10-08
CA2943711A1 (en) 2015-10-08
CN106456739A (zh) 2017-02-22
ES2853773T3 (es) 2021-09-17
US10624961B2 (en) 2020-04-21
CA2943007A1 (en) 2015-10-08
AU2015239025A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
IL283058B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL269830B1 (en) Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
MX2016012932A (es) Procedimientos novedosos para inducir una respuesta inmune.
HUE047784T2 (hu) Anti-TIM3 antitestek és alkalmazási eljárások
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
EP4070818A3 (en) Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
EP3134510A4 (en) Recombinant listeria vaccine strains and methods of producing the same
EP3200831A4 (en) Vaccines having an antigen and interleukin-21 as an adjuvant
EP3112378A4 (en) Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
EP3288538A4 (en) Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines
EP3204414A4 (en) Novel anti-nodal antibodies and methods of using same
MY191539A (en) Streptococcal vaccine
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
EP3107567A4 (en) Methods of modulating an immune response
EP3178491A4 (en) Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition
EP3010340A4 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
ZA201608487B (en) Dual adjuvant vaccine compositions, preparation and uses
DK3352783T3 (da) Vaccine omfattende immun-isolerede celler som producerer en immunmodulator
PL3402802T3 (pl) Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym
EP3151858A4 (en) Antibody guided vaccines and methods of use for generation of rapid mature immune responses
EP3104887A4 (en) Vaccines with interleukin-17 as an adjuvant
SI3140416T1 (sl) Kokultivacija propionibakterije in kvasovke
EP3097420A4 (en) Methods and compositions for immune dis-inhibition
EP3170068A4 (en) Using timing of character input to verify password
EP3197558A4 (en) Compositions and methods for transient immune response modulation during vaccination